A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Young Saing | - |
dc.contributor.author | Sym, Sun Jin | - |
dc.contributor.author | Park, Se Hoon | - |
dc.contributor.author | Park, Inkeun | - |
dc.contributor.author | Hong, Junshik | - |
dc.contributor.author | Ahn, Hee Kyung | - |
dc.contributor.author | Park, Jinny | - |
dc.contributor.author | Cho, Eun Kyung | - |
dc.contributor.author | Lee, Woon Ki | - |
dc.contributor.author | Chung, Min | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Shin, Dong Bok | - |
dc.date.available | 2020-02-28T18:43:34Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2014-01 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12926 | - |
dc.description.abstract | Docetaxel, in combination with cisplatin or oxaliplatin, has demonstrated efficacy in advanced gastric cancer (AGC). This randomized, non-comparative phase II trial evaluated two weekly docetaxel-based regimens to determine which is the most promising in terms of efficacy and safety as a front-line therapy in AGC. Chemotherapy-na < ve patients with measurable unresectable and/or metastatic gastric adenocarcinoma were randomly assigned to receive docetaxel (35 mg/m(2)) weekly on days 1 and 8 of a 21-day cycle plus either cisplatin (60 mg/m(2) on day 1) (wDP) or oxaliplatin (120 mg/m(2) on day 1) (wDO). Of the 77 randomly assigned patients, 76 patients (38 per arm) received one of the study treatments. Overall, response rate (ORR) was 37 % for wDP and 41 % for wDO. Median progression-free survival (PFS) was 4.9 and 4.4 months for wDP and wDO, respectively, and median overall survival (OS) was 9.7 and 12.3 months, respectively. Exploratory analyses showed no significant difference between wDP and wDO in terms of ORR (P = 0.707), PFS (P = 0.324), or OS (P = 0.581). The main grade 3 or 4 toxicity in the wDP and wDO groups was neutropenia (47 % in both groups). wDO was less associated with nausea (66 vs. 82 %) and vomiting (39 vs. 63 %), but more associated with peripheral neuropathy (68 vs. 39 %) than wDP. Rates of overall grade 3 or 4 adverse events were similar (wDP 66 vs. wDO 68 %). wDP and wDO were found to be equally active and tolerable as front-line treatments in AGC. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.subject | DOCETAXEL PLUS CISPLATIN | - |
dc.subject | CELL LUNG-CANCER | - |
dc.subject | FOLINIC ACID | - |
dc.subject | OXALIPLATIN | - |
dc.subject | TRIAL | - |
dc.subject | FLUOROURACIL | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | ADENOCARCINOMA | - |
dc.subject | COMBINATION | - |
dc.subject | CAPECITABINE | - |
dc.title | A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000329223200019 | - |
dc.identifier.doi | 10.1007/s00280-013-2334-3 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.73, no.1, pp.163 - 169 | - |
dc.identifier.scopusid | 2-s2.0-84892786410 | - |
dc.citation.endPage | 169 | - |
dc.citation.startPage | 163 | - |
dc.citation.title | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.volume | 73 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Kim, Young Saing | - |
dc.contributor.affiliatedAuthor | Sym, Sun Jin | - |
dc.contributor.affiliatedAuthor | Park, Inkeun | - |
dc.contributor.affiliatedAuthor | Hong, Junshik | - |
dc.contributor.affiliatedAuthor | Ahn, Hee Kyung | - |
dc.contributor.affiliatedAuthor | Park, Jinny | - |
dc.contributor.affiliatedAuthor | Cho, Eun Kyung | - |
dc.contributor.affiliatedAuthor | Lee, Woon Ki | - |
dc.contributor.affiliatedAuthor | Chung, Min | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.contributor.affiliatedAuthor | Shin, Dong Bok | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Gastric cancer | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Docetaxel | - |
dc.subject.keywordAuthor | Cisplatin | - |
dc.subject.keywordAuthor | Oxaliplatin | - |
dc.subject.keywordPlus | DOCETAXEL PLUS CISPLATIN | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | FOLINIC ACID | - |
dc.subject.keywordPlus | OXALIPLATIN | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | FLUOROURACIL | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | CAPECITABINE | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.